Trial Profile
ITIC2 Trial - Topical Imiquimod versus Conization to Treat Cervical Intraepithelial Neoplasia: Randomised Controlled, Non-inferiority Trial
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 22 Feb 2022
Price :
$35
*
At a glance
- Drugs Imiquimod (Primary)
- Indications Cervical intraepithelial neoplasia; Squamous cell cancer
- Focus Therapeutic Use
- 14 Feb 2022 Results published in the Gynecologic Oncology
- 30 Oct 2016 Status changed from recruiting to discontinued.
- 02 Mar 2013 New source identified and integrated (European Clinical Trials Database, EudraCT2012-004518-32).